pPACK-SPIKE™ SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix
- Based on SBI’s popular and highly cited pPACKH1 Packaging System
- Uses codon-optimized SARS-CoV-2 “S” protein in place of VSV-G envelope protein
- Ideal for COVID-19 research, such as neutralization assays, under BSL2 conditions
- Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
- Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
- Compare to the widespread D614G Spike protein by using pPACK-SPIKE D614G
- Start discovery and development with the mouse-adapted N501Y Spike protein by using pPACK-SPIKE N501Y
Products
| Catalog Number | Description | Size | Price | Quantity | Add to Cart | |||
|---|---|---|---|---|---|---|---|---|
| CVD19-500A-1 | pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix | 10 Reactions | $702 |
|
||||
| CVD19-510A-1 | pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix (XL) | 25 Reactions | $1399 |
|
||||
| CVD19-520A-KIT | pPACK-SPIKE Combo Kit, includes Cat# CVD19-500A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) | 1 Kit | $1183 |
|
||||
Overview
Overview
Safely study SARS-CoV-2 interactions
Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix speeds and simplifies the preparation of lentiviral particles pseudotyped with the SARS-CoV-2 Spike glycoprotein. Based on SBI's highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE Packaging Mix consists of three plasmids that produce all of the structural and replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.
For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for pPACK-SPIKE studies, or for creating lentivirus particles pseudotyped with the envelope protein of your choice. In addition, you can compare this Spike protein from the original Wuhan-Hu-1 strain to the more prevalent (as of summer 2020) D614G Spike protein with pPACK-SPIKE D614G.
- Based on SBI’s popular and highly cited pPACKH1 Packaging System
- Uses codon-optimized SARS-CoV-2 “S” protein (the original Wuhan-Hu-1 strain) in place of VSV-G envelope protein
- Efficiently incorporates the Spike protein into pseudoviral particles due to a 19 aa C-terminal truncation [1]
- Ideal for COVID-19 research, such as neutralization assays, under BSL2 conditions
- Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
- Available as a packaging mix or bundled into a convenient kit that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution
- Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
- Compare to the widespread D614G Spike protein by using pPACK-SPIKE D614G
- Start discovery and development with the mouse-adapted N501Y Spike protein by using pPACK-SPIKE N501Y
See all the available pPACK-SPIKE S protein variants:
| Catalog Number | Product Description | SPIKE PROTEIN MUTATION |
|---|---|---|
| CVD19-500A-1 | pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix | Original Wuhan-Hu-1 strain |
| CVD19-590A-1 | pPACK-SPIKE Alpha (B.1.1.7), SARS-CoV-2 "S" Pseudotype - Alpha (B.1.1.7, UK) Variant - Lentivector Packaging Mix | ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H |
| CVD19-640A-1 | pPACK-SPIKE Beta (B.1.351), SARS-CoV-2 "S" Pseudotype - Beta (B.1.351) Variant - Lentivector Packaging Mix | L18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V |
| CVD19-650A-1 | pPACK-SPIKE Delta (B.1.617.2), SARS-CoV-2 "S" Pseudotype - Delta (B.1.617.2) Variant - Lentivector Packaging Mix | T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N |
| CVD19-630A-1 | pPACK-SPIKE Gamma (P1), SARS-CoV-2 "S" Pseudotype - Gamma (P1) Variant - Lentivector Packaging Mix | L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F |
| CVD19-660A-1 | pPACK-SPIKE Omicron (B.1.1.529), SARS-CoV-2 "S" Pseudotype - Omicron (B.1.1.529) Variant - Lentivector Packaging Mix | A67V, Δ69-70, T95I, Δ142-144, Y145D, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S,Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F |
| CVD19-530A-1 | pPACK-SPIKE D614G, SARS-CoV-2 “S” Pseudotype – D614G Mutant – Lentivector Packaging Mix | D614G |
| CVD19-560A-1 | pPACK-SPIKE N501Y, SARS-CoV-2 "S" Pseudotype - N501Y Mutant - Lentivector Packaging Mix | N501Y |
| CVD19-610A-1 | pPACK-SPIKE B.1.429, SARS-CoV-2 "S" Pseudotype - B.1.429 (CAL.20C) Variant - Lentivector Packaging Mix | S13I, W152C, L452R, & D614G |
| CVD19-620A-1 | pPACK-SPIKE B.1.525, SARS-CoV-2 "S" Pseudotype - B.1.525 Variant - Lentivector Packaging Mix | ΔH69/V70, Q52R, E484K, D614G, Q677H, & F888L |
| CVD19-580A-1 | pPACK-SPIKE B.1.351 RBD Mutations Lentivector Packaging Mix | K417N, E484K, & N501Y |
| CVD19-600A-1 | pPACK-SPIKE B.1.351 S1 Mutations (RBD+D614G) Lentivector Packaging Mix | K417N, E484K, N501Y, & D614G |
| LV550A-1 | pPACK-BALD™ (Negative Control Packaging Mix) | An envelope protein-free negative control for pPACK-SPIKE |
References
- Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.
How It Works
How It Works
pPACK-SPIKE is easy to use—simply co-transfect the pPACK-SPIKE Plasmids and your lentivector construct into 293TN producer cells or other lentiviral production cells, isolate pseudoviral particles with an optional concentration step, and conduct your studies.
Supporting Data
Supporting Data
Figure 1. pPACK-SPIKE pseudovirus particles efficiently infect ACE2 overexpression cells. pPACK-SPIKE packaging mix was used to generate Spike pseudoviral particles carrying a GFP-reporter vector, concentrated using PEG-it Concentration Reagent, and transduced ACE2-overexpressing cells. GFP imaging shows expression of the GFP reporter only in cells overexpressing ACE2, demonstrating the SARS-CoV-2-like behavior of the Spike pseudoviral particles. Data courtesy of Henry David Herce and Michelle Prew from Dana-Farber Cancer Institute and Harvard Medical School.
FAQs
Resources
Related Products
Citations
Products
| Catalog Number | Description | Size | Price | Quantity | Add to Cart | |||
|---|---|---|---|---|---|---|---|---|
| CVD19-500A-1 | pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix | 10 Reactions | $702 |
|
||||
| CVD19-510A-1 | pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix (XL) | 25 Reactions | $1399 |
|
||||
| CVD19-520A-KIT | pPACK-SPIKE Combo Kit, includes Cat# CVD19-500A-1, plus PureFection Transfection Reagent (Cat# LV750A-1) and PEG-it Virus Concentration solution (Cat# LV810A-1) | 1 Kit | $1183 |
|
||||
Overview
Overview
Safely study SARS-CoV-2 interactions
Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix speeds and simplifies the preparation of lentiviral particles pseudotyped with the SARS-CoV-2 Spike glycoprotein. Based on SBI's highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE Packaging Mix consists of three plasmids that produce all of the structural and replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.
For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for pPACK-SPIKE studies, or for creating lentivirus particles pseudotyped with the envelope protein of your choice. In addition, you can compare this Spike protein from the original Wuhan-Hu-1 strain to the more prevalent (as of summer 2020) D614G Spike protein with pPACK-SPIKE D614G.
- Based on SBI’s popular and highly cited pPACKH1 Packaging System
- Uses codon-optimized SARS-CoV-2 “S” protein (the original Wuhan-Hu-1 strain) in place of VSV-G envelope protein
- Efficiently incorporates the Spike protein into pseudoviral particles due to a 19 aa C-terminal truncation [1]
- Ideal for COVID-19 research, such as neutralization assays, under BSL2 conditions
- Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
- Available as a packaging mix or bundled into a convenient kit that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution
- Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
- Compare to the widespread D614G Spike protein by using pPACK-SPIKE D614G
- Start discovery and development with the mouse-adapted N501Y Spike protein by using pPACK-SPIKE N501Y
See all the available pPACK-SPIKE S protein variants:
| Catalog Number | Product Description | SPIKE PROTEIN MUTATION |
|---|---|---|
| CVD19-500A-1 | pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging Mix | Original Wuhan-Hu-1 strain |
| CVD19-590A-1 | pPACK-SPIKE Alpha (B.1.1.7), SARS-CoV-2 "S" Pseudotype - Alpha (B.1.1.7, UK) Variant - Lentivector Packaging Mix | ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H |
| CVD19-640A-1 | pPACK-SPIKE Beta (B.1.351), SARS-CoV-2 "S" Pseudotype - Beta (B.1.351) Variant - Lentivector Packaging Mix | L18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V |
| CVD19-650A-1 | pPACK-SPIKE Delta (B.1.617.2), SARS-CoV-2 "S" Pseudotype - Delta (B.1.617.2) Variant - Lentivector Packaging Mix | T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N |
| CVD19-630A-1 | pPACK-SPIKE Gamma (P1), SARS-CoV-2 "S" Pseudotype - Gamma (P1) Variant - Lentivector Packaging Mix | L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F |
| CVD19-660A-1 | pPACK-SPIKE Omicron (B.1.1.529), SARS-CoV-2 "S" Pseudotype - Omicron (B.1.1.529) Variant - Lentivector Packaging Mix | A67V, Δ69-70, T95I, Δ142-144, Y145D, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S,Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F |
| CVD19-530A-1 | pPACK-SPIKE D614G, SARS-CoV-2 “S” Pseudotype – D614G Mutant – Lentivector Packaging Mix | D614G |
| CVD19-560A-1 | pPACK-SPIKE N501Y, SARS-CoV-2 "S" Pseudotype - N501Y Mutant - Lentivector Packaging Mix | N501Y |
| CVD19-610A-1 | pPACK-SPIKE B.1.429, SARS-CoV-2 "S" Pseudotype - B.1.429 (CAL.20C) Variant - Lentivector Packaging Mix | S13I, W152C, L452R, & D614G |
| CVD19-620A-1 | pPACK-SPIKE B.1.525, SARS-CoV-2 "S" Pseudotype - B.1.525 Variant - Lentivector Packaging Mix | ΔH69/V70, Q52R, E484K, D614G, Q677H, & F888L |
| CVD19-580A-1 | pPACK-SPIKE B.1.351 RBD Mutations Lentivector Packaging Mix | K417N, E484K, & N501Y |
| CVD19-600A-1 | pPACK-SPIKE B.1.351 S1 Mutations (RBD+D614G) Lentivector Packaging Mix | K417N, E484K, N501Y, & D614G |
| LV550A-1 | pPACK-BALD™ (Negative Control Packaging Mix) | An envelope protein-free negative control for pPACK-SPIKE |
References
- Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.
How It Works
How It Works
pPACK-SPIKE is easy to use—simply co-transfect the pPACK-SPIKE Plasmids and your lentivector construct into 293TN producer cells or other lentiviral production cells, isolate pseudoviral particles with an optional concentration step, and conduct your studies.Supporting Data
Supporting Data
Figure 1. pPACK-SPIKE pseudovirus particles efficiently infect ACE2 overexpression cells. pPACK-SPIKE packaging mix was used to generate Spike pseudoviral particles carrying a GFP-reporter vector, concentrated using PEG-it Concentration Reagent, and transduced ACE2-overexpressing cells. GFP imaging shows expression of the GFP reporter only in cells overexpressing ACE2, demonstrating the SARS-CoV-2-like behavior of the Spike pseudoviral particles. Data courtesy of Henry David Herce and Michelle Prew from Dana-Farber Cancer Institute and Harvard Medical School.